EMA Application withdrawn: Raligize — FGK Representative Service GmbH

View source ↗

Summary

The EMA withdrew the application for Raligize (FGK Representative Service GmbH) with a stated therapeutic area of uterine cervical neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cervical Neoplasms

Drugs mentioned

• Raligize

Snippet

Status: Application withdrawn. Therapeutic area: Uterine Cervical Neoplasms. MAH: FGK Representative Service GmbH. Decision date: 27/07/2018